ES2563577T3 - Uso de Mycobacterium bovis BCG eliminada mediante Liofilización Prolongada (LP) para prevenir o tratar la aterosclerosis - Google Patents

Uso de Mycobacterium bovis BCG eliminada mediante Liofilización Prolongada (LP) para prevenir o tratar la aterosclerosis Download PDF

Info

Publication number
ES2563577T3
ES2563577T3 ES10754572.5T ES10754572T ES2563577T3 ES 2563577 T3 ES2563577 T3 ES 2563577T3 ES 10754572 T ES10754572 T ES 10754572T ES 2563577 T3 ES2563577 T3 ES 2563577T3
Authority
ES
Spain
Prior art keywords
mice
bcg
pbs
mycobacterium bovis
bovis bcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10754572.5T
Other languages
English (en)
Spanish (es)
Inventor
Gilles Marchal
Micheline Lagranderie
Isabelle Schwartz-Cornil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Recherche Agronomique
Institut Pasteur
Original Assignee
Institut National de la Recherche Agronomique
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Recherche Agronomique, Institut Pasteur filed Critical Institut National de la Recherche Agronomique
Application granted granted Critical
Publication of ES2563577T3 publication Critical patent/ES2563577T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES10754572.5T 2009-08-13 2010-08-12 Uso de Mycobacterium bovis BCG eliminada mediante Liofilización Prolongada (LP) para prevenir o tratar la aterosclerosis Active ES2563577T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290627A EP2292260A1 (en) 2009-08-13 2009-08-13 Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
EP09290627 2009-08-13
PCT/IB2010/053652 WO2011018769A1 (en) 2009-08-13 2010-08-12 Use of mycobacterium bovis bcg killed by extended freeze drying (efd) for preventing or treating atherosclerosis

Publications (1)

Publication Number Publication Date
ES2563577T3 true ES2563577T3 (es) 2016-03-15

Family

ID=41402542

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10754572.5T Active ES2563577T3 (es) 2009-08-13 2010-08-12 Uso de Mycobacterium bovis BCG eliminada mediante Liofilización Prolongada (LP) para prevenir o tratar la aterosclerosis

Country Status (7)

Country Link
US (1) US8414865B2 (enExample)
EP (2) EP2292260A1 (enExample)
JP (1) JP5762407B2 (enExample)
CA (1) CA2770915C (enExample)
DK (1) DK2464378T3 (enExample)
ES (1) ES2563577T3 (enExample)
WO (1) WO2011018769A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013106785B4 (de) 2013-06-28 2018-11-29 Pilz Auslandsbeteiligungen Gmbh Verfahren zur Synchronisation eines Lichtgitters und auf diesem Verfahren beruhendes Lichtgitter
WO2015057968A2 (en) 2013-10-17 2015-04-23 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
JP6628071B2 (ja) * 2015-04-28 2020-01-08 国立大学法人北海道大学 低密度リポタンパク質酸化抑制剤
WO2017059132A1 (en) * 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
WO2020115161A1 (en) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant for use against pathogens
WO2024180083A1 (en) * 2023-02-27 2024-09-06 Westfälische Wilhelms-Universität Münster Oral vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US6350457B1 (en) * 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
ATE466585T1 (de) 2001-12-11 2010-05-15 Pasteur Institut Präparationen grampositiver bakterien zur behandlung von krankheiten mit immunfehlregulation
CA2531261A1 (en) 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
EP1916000A1 (en) * 2006-10-26 2008-04-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of measles virus nucleoprotein for treating atherosclerosis
EP2087898A1 (en) * 2008-02-06 2009-08-12 Institut Pasteur A preparation of mycobacterium bovis BCG killed by extended freeze drying (EFD) for treating rheumatoid arthritis

Also Published As

Publication number Publication date
CA2770915C (en) 2017-12-05
WO2011018769A1 (en) 2011-02-17
EP2292260A1 (en) 2011-03-09
JP5762407B2 (ja) 2015-08-12
US8414865B2 (en) 2013-04-09
CA2770915A1 (en) 2011-02-17
US20120201856A1 (en) 2012-08-09
EP2464378A1 (en) 2012-06-20
JP2013501775A (ja) 2013-01-17
EP2464378B1 (en) 2015-11-11
DK2464378T3 (en) 2016-02-08

Similar Documents

Publication Publication Date Title
Smits et al. Protective effect of Schistosoma mansoni infection on allergic airway inflammation depends on the intensity and chronicity of infection
Haspeslagh et al. The hygiene hypothesis: immunological mechanisms of airway tolerance
Realdi et al. Extradigestive manifestations of Helicobacter pylori Infection (Fact and fiction)
Nair et al. Immune polarization by hookworms: taking cues from T helper type 2, type 2 innate lymphoid cells and alternatively activated macrophages
DK2464378T3 (en) APPLICATION OF MYCOBACTERIUM BOVIS BCG HELD BY EXTENDED FREEZE DRYING (EFD) FOR PREVENTION OR TREATMENT OF Atherosclerosis
Silvane et al. A vaccine based on Kunitz-type molecule confers protection against Fasciola hepatica challenge by inducing IFN-γ and antibody immune responses through IL-17A production
ES2995333T3 (en) Phosphorylcholine conjugates and uses thereof
ES2345188T3 (es) Preparaciones de bacterias gram positivas para el tratamiento de enfermedades que comprenden una mala regulacion inmune.
Qu et al. L-theanine modulates intestine-specific immunity by regulating the differentiation of CD4+ T cells in ovalbumin-sensitized mice
Lucena et al. The immunoregulatory effects of co-infection with Fasciola hepatica: From bovine tuberculosis to Johne's disease
Kotomina et al. Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease
Fan et al. A novel PADRE-Kv1. 3 vaccine effectively induces therapeutic antibodies and ameliorates experimental autoimmune encephalomyelitis in rats
Seo et al. Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model
US9730988B2 (en) Parasitic biological agents for treatment and prevention of graft versus host disease
Kim et al. Therapeutic effects of Echinococcus granulosus cystic fluid on allergic airway inflammation
CA3080253A1 (en) Treatment of immune diseases by administration of antigen-specific formulations
De Haro et al. Attenuation of early atherosclerotic lesions by immunotolerance with β2 glycoprotein I and the immunomodulatory effectors interleukin 2 and 10 in a murine model
WO2013039872A1 (en) Compositions and methods for treating inflammatory bowel diseases
Endharti et al. Therapeutic effect of soluble worm protein acting as immune regulatory on colitis
Al-Refai et al. Effect of chamomile extract on the tongue of chemotherapy treated Albino rats (histopathological and immunohistochemical study)
Voehringer Basophils in immune responses against helminths
Grosche et al. Mucosal injury and inflammatory cells in response to brief ischaemia and reperfusion in the equine large colon
Wallace et al. Interleukin-10/Ceftriaxone prevents E. coli-induced delays in sensorimotor task learning and spatial memory in neonatal and adult Sprague–Dawley rats
KR20020021375A (ko) 미코박테리움 바카이를 활용하여 면역적으로 매개된질병을 치료하는 방법 및 조성물
Chinen et al. Advances in basic and clinical immunology in 2006